{
  "docId": "019de076-5923-773b-8485-b914b8e85d5b",
  "docSlug": "aa767e092bc23262b7b522a6b0c001e5",
  "documentTitle": "MindMed | Results Presentation Deck | 20 slides",
  "authorId": "mindmed",
  "authorName": "MindMed",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 20,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "key_messages",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-5923-773b-8485-b914b8e85d5b/8",
  "deckHref": "/decks/019de076-5923-773b-8485-b914b8e85d5b",
  "deckJsonHref": "/decks/019de076-5923-773b-8485-b914b8e85d5b.json",
  "deckAnchorHref": "/decks/019de076-5923-773b-8485-b914b8e85d5b#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.07,
        "w": 0.08,
        "x": 0.725,
        "y": 0.45
      },
      "kind": "image",
      "text": "House icon",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "303dcdda-5c80-4886-a285-4985d89a780d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.08,
        "x": 0.243,
        "y": 0.419
      },
      "kind": "image",
      "text": "Serotonin molecule icon",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7e1726f0-338b-4960-9eaf-2170a4dad410",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.14,
        "w": 0.72,
        "x": 0.14,
        "y": 0.148
      },
      "kind": "list",
      "text": "We are optimizing MM-120 across indications through the study of various doses and regimens, such as in the current Phase 2a trial in ADHD. Approach could be applicable to additional serotonin-mediated conditions with the potential for additional innovative dose and regimen combinations",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8962d8cf-d1fa-4a3f-817e-85b757ef64b6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.38,
        "x": 0.095,
        "y": 0.58
      },
      "kind": "paragraph",
      "text": "MM-120 targets this key neurotransmitter system that is implicated in ADHD symptoms",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3175247b-52a3-4487-ba34-9ffc7820f66e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.38,
        "x": 0.585,
        "y": 0.58
      },
      "kind": "paragraph",
      "text": "Innovative treatment paradigms Phase 2a trial in ADHD exploring outpatient administration (20 µg twice weekly)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b6777137-4a2e-4aa0-859a-b30524085708",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.3,
        "x": 0.168,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "1. Wang LJ, Yu YH, Fu ML et al. 2018; Sci Rep 8(1):10229.",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a3818a2f-ddb1-4be3-9aa1-e16b9205c638",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.038,
        "w": 0.812,
        "x": 0.038,
        "y": 0.048
      },
      "kind": "title",
      "text": "MM-120 | Proof-of-Concept of Outpatient Delivery in ADHD",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "693cfce1-583c-4be7-869b-60244ab7124d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 8,
      "beatId": "43b0daed-c25d-4529-ba07-29b26d748e8f",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "Slides 8-14 provide evidence and proof of concept for MindMed's product candidates.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 4,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "b638ff59-97f7-4353-9280-5fdfd3586639",
      "evidence": "The key takeaways and key messages slides provide an overview of MindMed's goals and strengths.",
      "position": 1,
      "objective": "Why is MindMed well-positioned to address brain health disorders?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}